Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
78.2M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
836K
-
Shares change
-
+631K
-
Total reported value, excl. options
-
$1.02M
-
Value change
-
+$723K
-
Number of buys
-
7
-
Number of sells
-
-6
-
Price
-
$1.21
Significant Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q2 2024
16 filings reported holding IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2024.
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 836K shares
of 78.2M outstanding shares and own 1.07% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (590K shares), BLAIR WILLIAM & CO/IL (116K shares), CITADEL ADVISORS LLC (37.9K shares), GEODE CAPITAL MANAGEMENT, LLC (37.3K shares), RENAISSANCE TECHNOLOGIES LLC (20.8K shares), VANGUARD GROUP INC (16.7K shares), STATE STREET CORP (10.1K shares), Tower Research Capital LLC (TRC) (5.74K shares), MORGAN STANLEY (1.67K shares), and MATHER GROUP, LLC. (334 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.